Navigation Links
Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Date:11/4/2008

ent of CERE-110 was led by Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer and is a continuation of the pioneering work of Mark Tuszynski, M.D., Ph.D., Ceregene's co-founder and a professor of Neurosciences at UCSD," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Similar to the other therapies in our pipeline which target Parkinson's disease, ocular disorders and ALS (Lou Gehrig's disease), CERE-110 may have the ability to not only treat the symptoms of Alzheimer's disease but to protect dying neurons and potentially result in the slowing of disease progression."

About CERE-110

CERE-110 is composed of an adeno-associated viral (AAV) vector carrying the gene for NGF, a naturally occurring protein that maintains survival of nerve cells in the brain. CERE-110 is surgically injected into the Nucleus Basalis of Meynert (NBM), a brain region where cholinergic cell degeneration occurs in Alzheimer's disease. The cholinergic system is important in memory and cognitive function, and a restoration in the function of this system may improve memory in individuals with Alzheimer's disease. Delivery of NGF using an AAV vector should have the potential to induce sustained expression of NGF, resulting in long-lasting restoration of the function.

The Phase 1 study was conducted at Rush University Medical Center, Chicago and UCSD. The open-label study involved 10 subjects with mild-to-moderate Alzheimer's disease. The administration of CERE-110 was generally safe and well tolerated. The 10 participants underwent cognitive testing, measures of activities of daily living, MRI scans and PET (positron emission tomography) scans. Increases in brain metabolism were observed in several cortical regions at six months and 12 months (p < 0.05) in four subjects as compared to other severity-matched individuals with Alzheimer's disease suggesting a potential reversal of patterns typically obser
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
2. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
3. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
4. Phase 2a Data for MEDI-528 Presented at CHEST 2008
5. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
6. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
7. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
8. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
9. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
10. Assessing the quality of phase I clinical trial abstracts
11. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Angeldress.co.uk is a popular ... occasion outfits for worldwide clients. According to Leo, the ... opening the first flagship retail store. Moreover, it is ... company has unveiled its new range of amazing wedding ... its new products are offered at greatly discounted prices, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 There’s ... interruptions, giving girls of all ages an all-natural ... company founded by women, for women, announces the ... (http://GirlU.com) to relieve the symptoms commonly ... and irritability. , As a lifelong health ...
(Date:9/17/2014)... San Diego, CA (PRWEB) September 17, 2014 ... Dermatology in San Diego, Dr. William Groff, an expert on ... of treating it. Pearly penile papules , or PPP, ... twenties and thirties, although other men may be affected as ... head of the penis. , “While PPP is not ...
(Date:9/17/2014)... 17, 2014 A raucous childhood in ... together to form author Nancy Chovancek’s laughter-filled new book, ... a collection of short stories that prove the best ... With a positive message of empowerment and resilience, everyone ... a proven author with two books under her belt ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3
... 2007 A review published in Dermatologic Therapy reveals that ... the same way as women but require higher doses of ... become a growing interest in cosmetic procedures by men. Although ... male patients who seek treatment is slowly increasing. , ...
... ceremony of, facility being built to serve the western Palm ... ... Dec. 28 The Health Care District,of Palm Beach County Board ... Board of Directors recently,dedicated the 50 acres of land on which ...
... plus fluticasone therapy led to better health, large trial ... People suffering with chronic obstructive pulmonary disease (COPD) may ... risk of death within two years as well and ... new research suggests. , The conclusion is drawn ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
... of the Philadelphia Ronald McDonald House, will ... Ceremony on, Thursday, January 3rd; House ... PHILADELPHIA, Dec. 28 The 27,000-square-foot,three-story "Philadelphia Ronald ... its doors on Monday, January 7, 2008 - ...
Cached Medicine News:Health News:Work Begins on New Regional Hospital Medical Campus 2Health News:Work Begins on New Regional Hospital Medical Campus 3Health News:Work Begins on New Regional Hospital Medical Campus 4Health News:Drug Combo Halves Death Risk for Severe COPD Patients 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
(Date:9/17/2014)... Mindray (NYSE: MR)announced its new generation DC-70 ... has been showcased for the first time at ISUOG ... and is scheduled for availability in the U.S. market ... most efficient workhorse in the mid-range segment, the DC-70 ... optimized user experience including a gesture-sensitive touch screen, delivering ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... the following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
Breaking Medicine Technology:Quality Exams at Your Fingertips 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... (Nasdaq: VPHM ) today announced that its ... cytomegalovirus (CMV) disease in liver transplant patients has been ... being moved to the current standard of care. The ... Phase 3 study of maribavir in stem cell transplant ...
... children for acute osteomyelitis--a bacterial bone infection--an early changeover ... just as effective as continuing the IV therapy, according ... more convenient for children and families, and avoid a ... from using central catheters, such as infections or breaks ...
Cached Medicine Technology:ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 2ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 3ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 4Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
... Intended for the quantitative ... serum. Reaction: kinetic, lag phase ... followed by linear phase of ... 340 nm. Linearity: 120 mg/dL ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Medicine Products: